Response to IQWiG assessment: Agendia’s Chief Clinical Officer affirms clinical utility of MammaPrint® in identifying breast cancer patients who can safely forego chemotherapy, following MINDACT trial

Gene expression-based tests are an integral part of modern oncology treatment strategies The MammaPrint® test, supported by the MINDACT study, reflects the leading edge technology and evidence for patients and physicians in need of clinically relevant information on which to … Continued

Three New Studies Presented at San Antonio Breast Cancer Symposium Further Demonstrate Value of MammaPrint® and BluePrint® in Individualizing Treatment for Breast Cancer Patients

Long-term follow-up of early-stage breast cancer patients shows significant difference in how gene expression-based tests classify patients for adjuvant chemotherapy treatment, finds MammaPrint® the best predictor of distant cancer recurrence MINT trial confirms stratification of patients classified by MammaPrint as … Continued

Agendia Expands its Business Activities in Germany

The “BRIDGE” initiative offers German patients free access to Agendia’s MammaPrint® breast cancer recurrence assay Data from the MINDACT trial shows MammaPrint is the only test on the German market supported by the highest level of medical evidence (1A) IRVINE, … Continued

Agendia Responds to “Clinical Insights on MINDACT”

  Dear Dr. Febbo, I recently received an email from you, in which you provided your unsolicited “Clinical Insights on MINDACT”.  I have been a practicing medical oncologist for nearly 30 years, the last 20 of which have been devoted … Continued